Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7301909 | 0.98 | LMNA (0.59) | LTA4HLMNATSHRSLC6A3HRH3 | |
| SCHEMBL30128338 | 0.96 | LTA4H (0.56) | LTA4HLMNATSHRSLC6A3HRH3 | |
| SCHEMBL5788869 | 0.83 | SIGMAR1 (0.59) | LTA4HTSHRSLC6A3SIGMAR1 | |
| SCHEMBL4438692 | 0.83 | POLB (0.53) | LTA4HLMNATSHRSIGMAR1HTT | |
| SCHEMBL13992754 | 0.82 | TSHR (0.47) | LTA4HLMNATSHRSIGMAR1 | |
| SCHEMBL29447351 | 0.81 | LTA4H (0.87) | LTA4HSLC6A3HRH3SIGMAR1HTT | |
| SCHEMBL6393260 | 0.79 | LTA4H (0.84) | LTA4HLMNASLC6A3HRH3SIGMAR1 | |
| SCHEMBL5188945 | 0.79 | TEAD3 (0.52) | LMNATSHRKDM4ESMN1; SMN2 | |
| SCHEMBL22440218 | 0.78 | LTA4H (0.77) | LTA4HSLC6A3HRH3SIGMAR1HTT | |
| SCHEMBL15841445 | 0.77 | LTA4H (0.42) | LTA4HLMNATSHRHRH3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126133-A | Compound and application thereof | 中国海洋大学 | 2023-11-28 | — | — | CN | disclosed |
| EP-3710439-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| CN-101005835-A | 1-[(3r)-amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2r)-carboxylic acid-benzyl amine derivatives and related compounds as dipeptidyl-peptidase iv (dpp-iv) inhibitors for the treatment of type 2 diab | SANTHERA PHARMACEUTICALS CH (CH) | 2007-07-25 | — | — | CN | disclosed |
| EP-1791536-A1 | 1-[(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL]-PYRROLIDINE-(2R)-CARBOXYLIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-06-06 | — | — | EP | disclosed |
| CN-1905868-A | DPP-IV inhibitors | GRAFFINITY PHARMACEUTICALS AG (CH) | 2007-01-31 | — | — | CN | disclosed |
| US-7087626-B2 | Pyrrole derivatives as pharmaceutical agents | ELI LILLY AND COMPANY (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1613304-A1 | DPP-IV INHIBITORS | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005120494-A1 | 1-`(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL !-PYRROLIDINE-(2R)-CARBOXILIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
| EP-1604662-A1 | 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-12-14 | — | — | EP | disclosed |
| EP-1372692-A4 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INST CANCER (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
| EP-1541143-A1 | DPP-IV INHIBITORS | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2005-06-15 | — | — | EP | disclosed |
| EP-1372692-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | Sloan Kettering Institute For Cancer Research (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002074050-A2 | ASYMMETRIC SYNTHESIS OF (S, S, R)-(-)-ACTINONIN AND ITS ANALOGS AND USES THEREFOR | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | LTA4H 1037/4885LMNA 2571/4885TSHR 1202/4885 |
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | LTA4H 936/4885LMNA 2300/4885TSHR 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.